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Ivermectin is an anthelmintic drug that works by inhibiting neuronal activity and muscular
contractility in arthropods and nematodes. It works by activating glutamate-gated chloride
channels (GluClRs) at nanomolar concentrations. These receptors, found exclusively
in invertebrates, belong to the pentameric Cys-loop receptor family of ligand-gated
ion channels (LGICs). Higher (micromolar) concentrations of ivermectin also activate
or modulate vertebrate Cys-loop receptors, including the excitatory nicotinic and the
inhibitory GABA type-A and glycine receptors (GlyRs). An X-ray crystal structure of
ivermectin complexed with the C. elegans α GluClR demonstrated that ivermectin binds
to the transmembrane domain in a cleft at the interface of adjacent subunits. It also
identified three hydrogen bonds thought to attach ivermectin to its site. Site-directed
mutagenesis and voltage-clamp electrophysiology have also been employed to probe
the binding site for ivermectin in α1 GlyRs. These have raised doubts as to whether
the hydrogen bonds are essential for high ivermectin potency. Due to its lipophilic
nature, it is likely that ivermectin accumulates in the membrane and binds reversibly (i.e.,
weakly) to its site. Several lines of evidence suggest that ivermectin opens the channel
pore via a structural change distinct from that induced by the neurotransmitter agonist.
Conformational changes occurring at locations distant from the pore can be probed using
voltage-clamp fluorometry (VCF), a technique which involves quantitating agonist-induced
fluorescence changes from environmentally sensitive fluorophores covalently attached to
receptor domains of interest. This technique has demonstrated that ivermectin induces
a global conformational change that propagates from the transmembrane domain to
the neurotransmitter binding site, thus suggesting a mechanism by which ivermectin
potentiates neurotransmitter-gated currents. Together, this information provides new
insights into the mechanisms of action of this important drug.
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INTRODUCTION
Ligand-gated ion channels (LGICs) of the pentameric Cys-loop
receptor family mediate most of the fast synaptic neurotransmis-
sion in the brain. The binding of a neurotransmitter ligand to the
extracellular domain of the Cys-loop receptor triggers the open-
ing of an intrinsic ion channel in its membrane-spanning domain,
allowing ions to diffuse down their electrochemical gradients
across the membrane (Changeux, 2010). As nicotinic acetyl-
choline receptors (nAChRs) and type-3 5-hydroxytryptamine
receptors (5-HT3Rs) are selective for cations, their activation
leads to depolarization and neuronal excitation. Conversely, as
the pores of receptors for γ-aminobutyric acid and glycine
(GABAARs and GlyRs) are selective for chloride, their activation
will tend to move the membrane potential rapidly toward the
chloride equilibrium potential. Because this lies near to the rest-
ing potential in adult neurons, chloride channel activation tends
to limit the ability of excitatory stimuli to depolarise the neuron.
Drugs that enhance the flux of chloride through inhibitory Cys-
loop receptors therefore inhibit neuronal activity in the brain or
spinal cord (Rudolph and Antkowiak, 2004).
Invertebrates often express a larger and more diverse array
of inhibitory Cys-loop receptor subunits than vertebrates (Jones
and Sattelle, 2008; Jones et al., 2010). For example, numerous
protostomes express glutamate-gated chloride channel receptors
(GluClRs), which are absent in vertebrates (Kehoe et al., 2009).
Hence, avermectins and milbemycins, which potently activate
GluClRs, lethally depress the nervous and muscular system of
GluClR-possessing species (Wolstenholme and Rogers, 2005),
and the gold standard avermectin anthelmintic, ivermectin, is
a well-tolerated and remarkably successful drug for eliminat-
ing parasitic nematodes and insects from mammals (Omura,
2008). Ivermectin also activates vertebrate GlyRs and GABAARs,
although less potently than GluClRs (Adelsberger et al., 2000;
Shan et al., 2001). Interestingly, its activation of Cys-loop recep-
tors is mechanistically distinct to that of neurotransmitter ago-
nists (Hibbs and Gouaux, 2011). Whereas the latter activate in
microseconds currents that are rapidly reversible, early tests with
ivermectin showed currents developed over a period of seconds
and were irreversible (Fritz et al., 1979; Kass et al., 1980). The
distinct actions of ivermectin make it useful for several reasons.
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It can be used to target vertebrate Cys-loop receptors for novel
therapeutic leads for a variety of indications. For example, drugs
that enhance the activity of GlyRsmay be useful for treating disor-
ders such as spasticity, epilepsy, tinnitus, breathing disorders, and
chronic pain (Costa and Diazgranados, 1994; Webb and Lynch,
2007; Eichler et al., 2009; Yevenes and Zeilhofer, 2011). Secondly,
receptors engineered to eliminate neurotransmitter sensitivity
and increase ivermectin sensitivity may be useful for the pharma-
cogenetic control of neurons in vivo (Lerchner et al., 2007; Lynagh
and Lynch, 2010b). Finally, an understanding of ivermectin bind-
ing and activation mechanisms may be useful for understand-
ing the molecular basis of ivermectin resistance in nematode
parasite pests (Wolstenholme et al., 2004; Wolstenholme, 2010;
Ghosh et al., 2012). Our understanding of ivermectin binding
and activation mechanisms has advanced rapidly in the past
12 months, with the publication of a crystal structure of iver-
mectin bound to the C. elegans α GluClR (Hibbs and Gouaux,
2011) and a systematic site-directed mutagenesis study on iver-
mectin sensitivity determinants at the α1 GlyR (Lynagh et al.,
2011). Thus, it is timely to bring together the knowledge of
how ivermectin modulates these channels, in order to facili-
tate the development of ivermectin-based therapies and neuronal
silencing tools.
Consistent with this review forming part of a series entitled
“Molecular probes and switches for functional analysis of recep-
tors, ion channels and synaptic networks,” we have focused on the
use of fluorescent techniques to probe conformational changes
elicited by ivermectin in Cys-loop ion channel receptors.
Cys-LOOP RECEPTOR STRUCTURE AND FUNCTION
The Cys-loop receptor family is diverse, with excitatory recep-
tors for acetylcholine, 5-hydroxytryptamine (5-HT), GABA and
zinc, and inhibitory receptors for acetylcholine, 5-HT, GABA,
glycine, glutamate, histamine, and even pH (Cully et al., 1994;
Ranganathan et al., 2000; Zheng et al., 2002; Beg and Jorgensen,
2003; Schnizler et al., 2005; Collingridge et al., 2009). However,
the tertiary structures and overarching mechanisms of activation
appear to be highly conserved. Before detailing the molecu-
lar mechanisms of ivermectin action on these receptors, it will
be useful to understand the common structural and functional
features of the family.
Functional Cys-loop receptors are formed by the assembly
of five of the same (homomer) or different (heteromer) sub-
units (Figures 1A,B). Each subunit consists of a large extra-
cellular N-terminal domain (ECD), four membrane-spanning
helices (M1–M4) that constitute the transmembrane domain
(TMD) and a short extracellular C-terminal domain. The ECD
consists of 10 β-strands; the loop between the sixth and sev-
enth is constrained by a disulfide bond between two highly
conserved cysteine residues, giving the family its name. The
subunits are arranged with five-fold symmetry, such that the
M2 helices from each subunit are located centrally, forming
the channel pore (Figure 1). The amino acid composition of
the M2 helix thus determines the ion selectivity and conduc-
tance properties of the channel (Imoto et al., 1988; Galzi et al.,
1992; Keramidas et al., 2000, 2002). To facilitate the compar-
ison of different subunits, a common numbering system is
used for M2 amino acid positions, starting with 0′, a highly
conserved positively charged amino acid near the intracellu-
lar C-terminal end. Moving outwards through the pore, posi-
tions 2′, 6′, 9′, 13′, and 16′ line the pore of most Cys-loop
receptor channels, according to their accessibility to hydrophilic
reagents and recent crystal structures (Akabas et al., 1994; Cymes
et al., 2005; Hibbs and Gouaux, 2011). At the –1′ position,
cationic Cys-loop channels generally possess a negatively charged
amino acid, whereas anionic channels possess a neutral residue
(Galzi et al., 1992).
NEUROTRANSMITTER ACTIVATION MECHANISMS
By the early 1990’s the genes for most human Cys-loop receptor
subunits had been cloned, enabling the expression of recombi-
nant receptors of known identity inmammalian cells and oocytes.
This in turn facilitated their examination by patch-clamp elec-
trophysiology (in the case of mammalian cells) or two-electrode
voltage-clamp electrophysiology (in oocytes). By mutating par-
ticular amino acids and testing for loss or gain of function, much
knowledge has accumulated on the molecular mechanisms of lig-
and binding, ionic selectivity, and receptor gating. Interpretation
of these functional data is now aided by X-ray crystallographic
structures of molluscan acetylcholine binding proteins (AChBPs),
pentamers that resemble the ECD of the nAChR (Brejc et al.,
2001), a GluClR crystal structure from C. elegans (Hibbs and
Gouaux, 2011) and an electron micrographic structure of the
nAChR (Unwin, 2005). X-ray crystallographic data on two pre-
sumably closed- and open-state bacterial homologs, ELIC, and
GLIC, also inform hypotheses on Cys-loop receptor activation
mechanisms (Hilf and Dutzler, 2008; Bocquet et al., 2009). In
the metazoan receptors, the agonist binding site is at the inter-
face of ECDs from two adjacent subunits. It is formed by three
loops A–C of the principal face and three to four loops (or
rather β-strands) D–G of the complementary face (Figure 1C).
Substitutions of residues in these loops in nAChRs, 5-HT3Rs,
GABAARs, GlyRs, and GluClRs thus cause large decreases in
agonist sensitivity (Galzi et al., 1991; Amin and Weiss, 1993;
Rajendra et al., 1995; Li et al., 2002; Hazai et al., 2009). Several
important ligand-binding residues are indicated in green in
Figure 1. Following ligand binding, a wave of conformational
changes proceeds away from the binding site toward the chan-
nel gate (Purohit et al., 2007) and numerous mutagenesis studies
have implicated amino acids involved in mediating these con-
formational changes (Miller and Smart, 2010; Thompson et al.,
2010).
Cysteine cross-linking in the GABAAR ECD and analysis of
AChBP and nAChR structures in liganded and unliganded con-
formations suggest that upon ligand binding, loops C and B
of the principal ligand binding face move toward the comple-
mentary face and around the agonist (Wagner and Czajkowski,
2001; Hansen et al., 2005; Unwin, 2005). Structural analyses
and molecular dynamics simulations suggest that this clockwise
movement of ECDs (when the pentamer is viewed from above,
as in Figure 1A) is coupled to a counter-clockwise rotation of
TMDs (Taly et al., 2005; Bocquet et al., 2009). There are sev-
eral obvious physical pathways along which the ECD movement
might cause TMD movement. β-strand 10, which forms Loop C
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FIGURE 1 | Cys-loop receptor structure. The homomeric α GluClR from
C. elegans viewed (A) from the extracellular space and (B) from within the
membrane plane. Individual subunits are shown in different colors.
(A) depicts the symmetrical arrangement of both the extracellular domains
and, centrally, of the M2 helices. These images are based on the original
X-ray crystallographic structure of 3.3 Å resolution (PDB ID 3RHW), which
was achieved by complexing the GluClR with an antigen-binding fragment,
ivermectin and lipids, and represents an activated, open-channel state (Hibbs
and Gouaux, 2011). The present images were produced using PyMOL
(Schrödinger, LLC). (C) Two adjacent subunits from (B), indicating functionally
significant parts of the Cys-loop receptor subunit. Green side chains indicate
α GluCl residues that bind the agonist glutamate (Hibbs and Gouaux, 2011).
As in most Cys-loop receptors, the agonist binding residues are located in
loops A-C from the principal subunit and loops D-G from the complementary
subunit, as indicated. Within the principal subunit, loop 2 (1), the conserved
Cys-loop (2), the pre-M1 domain (3), and the M2-M3 linker (4) are shown in
magenta; these structures physically couple agonist binding to channel
opening (see text). Blue side chains in both subunits indicate conserved 9’
hydrophobic residues (upper) and the 0′ basic residues (lower) that control
channel conductance and ionic selectivity.
with β-strand 9, is linked via the “pre-M1 domain” to M1 of the
TMD (Figure 1). Loops D and G (β-strands 2 and 1) form “loop
2” which dips toward the TMD, making close contact with the
“M2–M3 linker.” Finally, the conserved Cys-loop that connects
Loops E and B (β-strands 6 and 7) dips well into the helical bun-
dle of the individual subunit. Mutations in these domains often
alter the ability of bound ligand to activate the channel, because
they disrupt a specific set of ionic and hydrophobic links formed
across the interface of the ECD and TMD (Kash et al., 2003;
Grutter et al., 2005; Lee and Sine, 2005; Xiu et al., 2005; Pless et al.,
2011).
The closed channel is narrowest near its middle, where
the side chains from highly conserved M2 9′ leucine residues
form a hydrophobic girdle (Miyazawa et al., 2003; Hilf and
Dutzler, 2008). In defining how this gate is opened, various
groups have suggested that the M2 helices either rotate (Unwin,
1995; Horenstein et al., 2001), move apart without rotating
(Akabas et al., 1994; Cymes et al., 2005; Paas et al., 2005) or
tilt tangentially to the pore (Taly et al., 2005). Static pictures
of the closed and open states, as revealed by crystal structures,
show the upper halves of the M2 helices transitioning away from
the pore axis in the open state, such that the pore restriction
remains at the −2′ and +2′ side chains (Bocquet et al., 2009; Hilf
and Dutzler, 2009; Hibbs and Gouaux, 2011). This seems con-
sistent with the role of this region in forming the ion selectivity
filter because the charge filtering property of the pore is criti-
cally dependent upon its diameter (Galzi et al., 1992; Keramidas
et al., 2004; Cymes and Grosman, 2011). It is important to
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note, however, that these crystal structures depict ivermectin- or
proton-bound receptors, neither of which is a conventional lig-
and. Thus, an agreement on the structures of the resting closed
and the transmitter-induced open states, or the mechanism by
which the channel transitions from one state to the other, has not
been reached.
THE IVERMECTIN BINDING SITE IN Cys-LOOP RECEPTORS
Ivermectin comprises a mixture of 22,23-dihydroavermectin B1a
and B1b in a 80:20 ratio. These compounds differ in structure
only at C25, a part of the molecule not involved in binding. Given
the greater abundance and nematicidal efficacy of avermectin B1a
(Crump and Omura, 2011), it is conventional to refer to the
abovemixture as “ivermectin” and this usagewill be adopted here.
Ivermectin directly activates GlyRs, GluClRs, and GABAARs, gen-
erally via a mechanism that is either irreversible or very slowly
reversible (Cully et al., 1994; Etter et al., 1996; Adelsberger et al.,
2000; Shan et al., 2001; Hibbs and Gouaux, 2011). In addition,
at concentrations that are too low to produce direct activation,
ivermectin also potently enhances neurotransmitter-gated cur-
rents (Cully et al., 1994; Huang and Casida, 1997; Shan et al.,
2001). Ivermectin has not been shown to influence 5-HT3R activ-
ity, although at high (30μM) concentrations it potentiates α7
nAChRs (Krause et al., 1998; Raymond et al., 2000; Collins and
Millar, 2010).
It was first proposed many years ago that ivermectin might
interact with the TMD channel domain of Cys-loop receptors
(Pong and Wang, 1982; Martin and Kusel, 1992). However,
the molecular determinants of ivermectin binding have only
recently been identified. Hibbs and Gouaux have described at
high resolution ivermectin bound to the homomeric α GluClR
from C. elegans (Hibbs and Gouaux, 2011). Ivermectin binds at
the TMD interface of two adjacent subunits, wedged between
M3 from the principal subunit (“M3(+)”) and M1 from the
complementary subunit (“M1(−)”) (Figure 2A). The benzofu-
ran head of ivermectin is orientated toward the pore, such that
the C5-hydroxyl of ivermectin forms a hydrogen bond with the
hydroxyl side chain of a serine residue at the M2(+) 15′ position
(Figure 2B). The C7-hydroxyl of ivermectin forms a hydrogen
bond with the backbone carbonyl of an M1 leucine (218) residue,
but is also close enough to the carbonyl oxygen at the C1 posi-
tion of ivermectin to form a hydrogen bond with the latter
(Figure 2B). The spiroketal is oriented toward the cytoplasmwith
a hydrogen bond between a spiroketal oxygen and the hydroxyl
side chain of an M3 threonine (285). The disaccharide remains
outside the binding cleft in contact with the surrounding lipids
and the protein surface. There are an additional twelve van der
Waals interactions between ivermectin and M3(+), M2(+), and
M1(−) residues.
Mutagenesis experiments, combined with an homology model
based on the C. elegans α GluClR, reveal a similar binding orien-
tation for ivermectin in GlyRs. In the α1 GlyR, M3(+) Ala288Phe
and M1(−) Pro230Trp mutations were unique in that they
decreased both the direct agonist and potentiating effects of iver-
mectin, singling out these two residues as possible determinants
of ivermectin binding (Lynagh et al., 2011). Indeed, Ala288 and
Pro230 are equivalent to two of the α GluClR residues identified
FIGURE 2 | The ivermectin binding site in the C. elegans α GluClR
crystal structure. (A) The GluClR pentamer viewed from within the
membrane plane, with ECDs removed for clarity. At one subunit interface,
the residues that contact the bound ivermectin molecule are indicated in
green, showing that ivermectin binds to the receptor in the outer half of the
membrane. (B) Ivermectin (blue) bound to a subunit interface. Ivermectin
forms hydrogen bonds (red dashed lines) with (+)M3 threonine 285,
(+)M2 serine 15′ and the backbone carbonyl oxygen of (−)M1 leucine 218
(Hibbs and Gouaux, 2011). The orange dashed line indicates the 2.6 Å
proximity of the C7 hydroxyl oxygen and the C1 carbonyl oxygen of
ivermectin. Green indicates residues proximal to ivermectin, indicative of
hydrogen bonds or van der Waals interactions. Purple indicates residues
equivalent to those in the α1 GlyR (GlyR M3 leucine 291, M2 threonine 12′ ,
M1 leucine 233) whose substitution by tryptophan causes ivermectin to act
as an inhbitor (Lynagh et al., 2011). Orange indicates residues
(GluClR (+)M3 glycine 285 and (−)M1 223) that contribute van der Waals
interactions in the GluClR and whose substitution for larger residues
decreases ivermectin sensitivity in the α1 GlyR (the (−)M1 residue) or in
both α 1 GlyR and the H. contortus α3B GluCl (the (+)M3 residue) (Lynagh
and Lynch, 2010b; Lynagh et al., 2011). This figure uses the same PDB file
and software as Figure 1.
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by Hibbs and Gouaux as being involved in van der Waals inter-
actions with the ivermectin backbone macrocycle. Functional
experiments have shown that mutations to Ala288 in the α1
GlyR, or to the corresponding residue in the α3B GluClR, have
a particularly strong influence on ivermectin potency (Lynagh
and Lynch, 2010a). For example, if a glycine residue exists at
this site, as in the unmutated α3B GluClR or the Ala288Gly
mutant α1 GlyR, the recombinant receptors show an ivermectin
agonist EC50 around 40 nM. Alternately, if there is an alanine
residue at this site, as in the Gly329Ala mutant α3B GluClR
or in the unmutated α1 GlyR, the recombinant receptors show
an EC50 of 1.2μM. Larger substitutions at this position abol-
ish activation in both receptors (Lynagh and Lynch, 2010a). The
Gly323Asp mutation, at the equivalent position to Ala288, in
the α GluClR of the acarid, Tetranychus urticae, results in aver-
mectin resistance in this otherwise avermectin-sensitive species
(Kwon et al., 2010). Surprisingly, computational docking of iver-
mectin to a structural homology model of the mutant Ala288Gly
α1 GlyR predicts an ivermectin binding conformation almost
identical to that at the unmutated α1 GlyR, suggesting that the
ivermectin binding on-rate, rather than its binding energy, is
altered by this mutation (Lynagh et al., 2011). Taken together
with the site-directed mutagenesis information described above,
this suggests large side chains at the Ala288 equivalent posi-
tion constitute a barrier to ivermectin accessing its site, but
once ivermectin does bind the conformation is not affected by
the side chain at this position. The binding of tritiated milbe-
mycin A4 (similar to ivermectin but without the disaccharide)
to the α3B GluClR was recently shown to be abolished by the
Gly—Asp at the position corresponding to Ala288 (Yamaguchi
et al., 2012).
Hibbs and Gouaux suggested that ivermectin binding wedges
apart M3(+) and M1(−) helices in such a way as to move the
M2 helix from its resting closed state; the C5-hydroxyl/M2(+)
15′ hydrogen bond then serves to stabilise the M2 helix in its
open state. This is a mechanistic explanation of refreshing tan-
gibility. It could also explain the reduced nematicidal potency of
avermectins lacking the C5-hydroxyl (Michael et al., 2001) and
the finding that selamectin, which incorporates a C5-oxime, does
not activate the GlyR (Lynagh et al., 2011). However, this and
the other hydrogen bonds in the C. elegans α GluClR might not
be conserved in other highly ivermectin-sensitive Cys-loop recep-
tors. For example, potent ivermectin activation is still observed at
the Ser15′Ile mutant α1 GlyR (Lynagh et al., 2011) and at GluClRs
that naturally incorporate non-hydrogen bonding side chains at
the M2(+) 15′ and/or M3(+) Thr285 (α GluClR numbering)
positions (Cully et al., 1996; Forrester et al., 2003; Njue et al.,
2004; McCavera et al., 2009). Finally, C5-hydroxyl-substituted
milbemycins do not suffer the same loss of potency as C5-
hydroxyl-substituted avermectins (Tsukamoto et al., 1991). It may
be space at the M3(+)/M1(−) interface, rather than hydrogen
bonds, that most crucially determine avermectin and milbemycin
potency.
Ivermectin also potentiates the P2X4 subtype of ionotropic
ATP-gated ion channels, although it does not produce direct
activation in the absence of ATP (Khakh et al., 1999). These recep-
tors belong to a distinct structural family of ion channels that is
comprised of three subunits. Tryptophan scanning mutagenesis
of P2X4 receptors suggests that ivermectin binds at the lipid-
protein interface, possibly in a cleft between adjacent transmem-
brane α-helices (Silberberg et al., 2007). However, the location
of the ivermectin binding site has not yet been addressed in the
context of the recent crystal structure of a zebrafish P2X4 receptor
(Kawate et al., 2009).
DOES IVERMECTIN BIND REVERSIBLY?
There are two possible mechanisms to explain the apparent
irreversible activation by ivermectin of GlyRs, GluClRs, and
GABAARs. One is that it binds irreversibly, or covalently, to the
receptor. In this scenario, low ivermectin concentrations should
eventually occupy all sites and thus should eventually elicit max-
imal receptor activation. However, covalent interactions between
ivermectin and its site are not evident in the GluClR crystal struc-
ture, nor would they be expected to exist given the chemical
properties of ivermectin. The alternative explanation is that, due
to its lipophilic nature, ivermectin partitions into the membrane
where it reaches a high local concentration. Thus, much of the
binding energy of ivermectin could derive from the non-specific
free energy of membrane partitioning, with the actual ligand-
channel interaction being quite weak and thus reversible (Lee
and MacKinnon, 2004). Consistent with this model, ivermectin
has been shown to partition into phospholipid vesicles with an
estimated mole fraction partition coefficient of 104 (Bloom and
Matheson, 1993; Silberberg et al., 2007).
Single channel kinetic analysis is a direct method for assessing
the reversibility of a binding interaction. Each time a neuro-
transmitter agonist binds to a Cys-loop receptor it induces a
stochastic “burst” of single channel activity. The burst termi-
nates once the agonist dissociates from the channel. Thus, analysis
of both the burst duration and the inter-burst duration (i.e.,
the length of time between bursts) will allow one to determine
the rates at which the agonist binds and unbinds from its site
(Mortensen and Smart, 2007). It follows that if ivermectin binds
irreversibly, then it should induce an irreversible burst of chan-
nel activity. Alternately, if ivermectin binds reversibly, then it
should activate short stochastic bursts of activity. It may not be
straightforward to discern between these mechanisms if multi-
ple channels are present in a single patch. This is exemplified
in a study of ivermectin on muscle membrane from the nema-
tode Ascaris suum. Ivermectin initially induced the activation
of a single channel, although the number of active channels
increased over time to the extent that single channel activations
could no longer be detected (Martin and Pennington, 1989).
Adelsberger (Adelsberger et al., 2000) compared the effects of
ivermectin and GABA at mammalian α1β2γ2 GABAARs. They
showed by whole-cell recording that the rise-time and decay of
ivermectin-activated currents were markedly slower than those
of GABA-activated currents. Their single channel kinetic analy-
sis revealed that ivermectin did not differ from GABA in terms
of the two observed opening rate constants, although groups of
openings were markedly longer in the presence of ivermectin.
Thus, although ivermectin induces no desensitization and dis-
sociates at a slower rate than GABA, ivermectin-induced single
channel bursts were reversible, supporting the idea of ivermectin
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accumulating in the membrane and binding reversibly to the
channel.
IVERMECTIN ACTIVATION MECHANISMS
Several lines of evidence suggest that ivermectin and glycine
activate the GlyR via structurally distinct mechanisms. First,
ivermectin potently activates GlyRs that are completely desen-
sitized to glycine (Shan et al., 2001). Second, ivermectin- and
glycine-mediated currents exhibit distinct pharmacological
properties, implying different activated conformations (Shan
et al., 2001; Pless et al., 2007). Third, mutations that eliminate
glycine sensitivity frequently have little or no effect on iver-
mectin sensitivity and vice versa (Shan et al., 2001; Lynagh and
Lynch, 2010a; Lynagh et al., 2011). Finally, voltage-clamp flu-
orometry (VCF) experiments, to be described in further detail
below, show that conformational changes induced by the two
ligands are distinct (Pless et al., 2007; Wang and Lynch, 2012).
However, to date there has been no systematic attempt to inte-
grate these observations into a structural model of ivermectin
activation.
A mechanistic explanation as to why M3 movement should
have an effect on M2 to open the channel has recently been sug-
gested on the basis of experiments conducted on the bacterial
Cys-loop receptor homolog, GLIC. Mutagenesis and molecular
dynamics simulations of GLIC show that proton binding to an
M2 histidine side chain strengthens interactions between M2 and
M3 helices within a subunit (Wang et al., 2012). The authors pro-
pose that this enables the concerted rigid body movement of M2
and M3 helices which favors an open channel state, whereas in
the proton-free closed channel state, M2 is decoupled from M3.
Similarly, ivermectin binding to Cys-loop receptors might enable
a similar coupling of M2 and M3 helices; if the wedging apart
of M3(+) and M1(−) serves to “drag” M2 helices away from
the pore axis in a concerted M3/M2 conformational change, this
might provide an explanation for why mutations in the M2–M3
linker decrease the direct agonist potency and not the efficacy
with which ivermectin potentiates neurotransmitter-gated cur-
rents (Kane et al., 2000; Lynagh et al., 2011). In the potentiation
of GluClRs, GlyRs, and GABAARs by ivermectin (Cully et al.,
1994; Huang and Casida, 1997; Shan et al., 2001), wedging apart
M3(+) and M1(−) might decrease the energy required for neu-
rotransmitter agonists to effect M2 movement; in the activation
of these channels, a subsequent coupling of ivermectin andM2 or
of M2 and M3 might be required for direct activation. Similar
mechanisms might underlie the potentiation and activation of
GABAARs and GlyRs by the anaesthetic etomidate (Pistis et al.,
1997), which binds in the same cleft as occupied by ivermectin
(Li et al., 2006; Chiara et al., 2012).
If highly potent activation of the channel by ivermectin
requires it to form a hydrogen bond with an M2 residue (Hibbs
and Gouaux, 2011), then in most anionic Cys-loop receptors
there are several alternate polar side chains other than M2(+) 15′
that could be located close to the C5-hydroxyl of ivermectin to
form such a bond. These include the M2(+) 12′, M2(+) 19′, and
the M2(−) 14′ positions. The locations of these residues in the
ivermectin binding site are shown in Figure 3A and a sequence
alignment showing the identity of these residues in various
FIGURE 3 | Polar side chains near the ivermectin benzofuran. (A) (+)M3
and (+)M2 from the principal face and (−)M2 from the complementary face
of the ivermectin binding site in the α GluClR from C. elegans, as in
Figure 2A. Polar side chains close to the bound ivermectin molecule are
shown in cyan. The M3-Gly position crucial to ivermectin sensitivity is
shown in orange. (B) Amino acid sequence alignment of residues,
stretching from M2–12′ to M3-Gly positions. The four cyan side chains from
(A) are shown in bold in the alignment, in cyan if polar and in black if
neutral. The M3-Gly position is in orange. The α GluClR from C. elegans,
the α3B GluClR from H. contortus and the human α1 GlyR are activated by
ivermectin Cully et al. (1994); McCavera et al. (2009); Shan et al. (2001), the
UNC-49C (co-expressed with UNC-49B) GABA receptor from H. contortus
and the human α7 nAChR are not activated but are potentiated by
ivermectin (Brown et al., 2012); Krause et al. (1998), and the MOD-1 5-HT
receptor from C. elegans is insensitive to ivermectin (Ranganathan et al.,
2000).
Cys-loop receptor subunits is shown in Figure 3B. Both dis-
played α GluClR subunits are sensitive to nanomolar ivermectin
concentrations whereas the remaining subunits are not. As dis-
cussed above, the M3 glycine (shown in orange) is essential for
high ivermectin sensitivity. It is also evident that polar sidechains
at the positions indicated in blue (i.e., M2(+) 12′, M2(−)
14′, M2(+) 15′, and M2(+) 19′) are essential for high ivermectin
sensitivity. Hydrophobic residues (in black) are incompatible
with high ivermectin sensitivity, even if an M3-Gly is present.
Substitutions at any of these positions in the α1 GlyR either
convert ivermectin to an inhibitor of glycine currents or alter
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ivermectin agonist potency (Shan et al., 2001; Lynagh et al., 2011).
It is also notable that α7 nAChRs, which are potentiated but not
activated by ivermectin (Krause et al., 1998; Raymond et al., 2000;
Collins and Millar, 2010), possess neutral side chains at the 14′,
15′, and 19′ positions (Figure 3B).
Maximal activation of Cys-loop channels may require as few
as two bound ivermectin molecules. Perhaps the strongest evi-
dence for this comes from experiments on α1β heteromeric GlyRs
which most likely exist in a β-α1-β-α1-β subunit arrangement
(Grudzinska et al., 2005). When ivermectin binding to the α1
subunit was ablated by the Ala288Phe mutation, heteromeric
receptors were completely insensitive to ivermectin (Lynagh and
Lynch, 2010a). However, unmutated α1β heteromers exhibit a
similar ivermectin potency to α1 homomeric GlyRs (Shan et al.,
2001; Lynagh and Lynch, 2010a). This implies that ivermectin
maximally activates heteromeric GlyRs by binding only to the two
α(+)/β(−) interfaces (Lynagh and Lynch, 2010a).
VOLTAGE-CLAMP FLUOROMETRY TO DETECT
IVERMECTIN-INDUCED CONFORMATIONAL CHANGES
IN THE ECD
As described above, ivermectin must rearrange the TMD helical
organization in order to open the channel. This rearrangement is
in turn likely to induce a conformational change in the M2–M3
loop. If this is the case then mutation to the M2–M3 loop, or to
the ECD domains that interact closely with it, might be expected
to affect ivermectin gating efficacy. Indeed, mutations in the con-
served Cys-loop, the M2–M3 linker and the pre-M1 region of
GlyRs and GluClRs have been shown to decrease the efficacy with
which ivermectin gates the receptor (Kane et al., 2000; Lynagh
et al., 2011). At the GlyR, these mutations typically increased
ivermectin agonist EC50 values 7- to 14-fold without affecting
the potency with which ivermectin potentiated glycine-mediated
currents (Lynagh et al., 2011). This suggests that the mutations
did not disrupt ivermectin affinity, but rather the efficacy with
which it activated the receptor. Indeed, such mutations have been
shown to alter ivermectin and milbemycin binding per se to the
α3B GluClR (McCavera et al., 2009; Yamaguchi et al., 2012).
Given that ivermectin induces conformational changes at the
ECD-TMD interface, it is possible that it may “globally” alter
the conformation of the entire ECD. Understanding the struc-
tural basis of these conformational changes may have implications
for understanding the mechanism by which ivermectin potenti-
ates neurotransmitter-gated currents (Cully et al., 1994; Huang
and Casida, 1997; Shan et al., 2001) and permits glutamate to
bind to the α GluClR (Hibbs and Gouaux, 2011). Voltage- VCF is
one useful means of comparing glycine- and ivermectin-induced
conformational changes in the ECD.
VCF involves covalently attaching an environmentally sensi-
tive fluorophore to a receptor domain of interest. The first step
is to engineer a cysteine into the site of interest in an otherwise
cysteine-free protein. The protein, which is usually recombinantly
expressed in Xenopus oocytes, is then reacted with a fluorescent
reporter conjugated to a sulfhydryl-reactive group, normally a
methanethiosulfonate (MTS) or maleimide. Rhodamine deriva-
tives appear to be retaining their popularity as the most widely
used fluorophores for these types of experiments. However, many
other fluorophores have been successfully used, and fluorophore
selection is largely a matter of trial and error (Pless and Lynch,
2008). In our laboratory, we routinely employ four fluorophores
and generally only analyse results from one that gives the large flu-
orescence response at a given labeled site (Pless and Lynch, 2009;
Wang and Lynch, 2012).
Although the choice of light sourcemay depend on the spectral
properties of the fluorophore, we find that a 100–150 watt halo-
gen lamp gives best results. Xenon and mercury burners can also
be used, although these generate increased light noise and their
intensity is not as easily controlled. A standard inverted epifluo-
rescence microscope is suitable for most VCF applications (Pless
and Lynch, 2008). Electrophysiology can be performed using
standard two-electrode voltage-clamp and fluorescence signals
can be measured simultaneously using a photomultiplier or pho-
todiode. VCF takes advantage of the fact that the quantum yield
of many organic fluorophores is highly sensitive to the chemical
nature of their environment. For example, the fluorescence inten-
sity of rhodamine increases with hydrophobicity (Gandhi and
Isacoff, 2005). Thus, if a ligand-induced conformational change
produces a rearrangement that alters the microenvironment of
an attached fluorophore, this may be reported as a fluorescence
change. Detecting a conformational change with this technique
is one thing: it is another matter entirely to resolve its structural
basis. Indeed, the authors are not aware of any study to date that
has successfully identified the structural basis of any conforma-
tional change as detected by a single fluorescent reporter.
The main advantage of VCF over conventional electrophys-
iology is that it offers a means of quantitating conformational
changes occurring in real time at a domain of interest, distant
from the pore, on the external protein surface. Specifically, VCF
can provide information about (1) the temporal resolution of
domain movements during gating in voltage-gated channels, (2)
whether all subunits (e.g., liganded and unliganded) respond
similarly during ligand-induced activation, (3) whether differ-
ent ligands produce different conformational changes in a given
subunit. One of the limitations of VCF is that it is difficult
to unequivocally determine whether a detected conformational
change is part of the gating process or whether it is detecting a
peripheral event that does not contribute to the “conformational
wave” that induces activation. Single channel kinetic analysis (i.e.,
patch clamp electrophysiology) provides a definitive means of
assessing the contribution of a residue to the channel gating
mechanism (Auerbach, 2010).
VCF was recently employed in our laboratory to compare
glycine- and ivermectin-induced conformational changes in the
α1 GlyR to address two questions: (1) does ivermectin elicit a
global conformational change that extends into the ECD and
perhaps to the glycine binding site? and (2) are these confor-
mational changes distinct from those elicited by glycine? We
investigated 12 cysteine-substituted sites throughout the α1 GlyR
ECD that were all known to produce glycine-mediated conforma-
tional changes when labeled with rhodamine derivatives (Wang
and Lynch, 2012). Most (9/12) of these labeled sites, includ-
ing those located in glycine binding domain loops C, E, and F
(Figure 1C), exhibited robust fluorescence changes in response to
glycine binding but no detectable fluorescence change in response
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to ivermectin binding. An example of a differential fluorescence
response for the H201C mutant GlyR is shown in Figure 4A.
However, at the remaining three labeled sites (N203C in bind-
ing domain loop C, Q67C in binding domain loop D, and V178C
in binding domain loop F), ivermectin and glycine both elicited
detectable fluorescence changes (Figure 4B). Moreover, it has
previously been shown that the L233W mutation converts iver-
mectin into an antagonist of glycine-gated currents (Lynagh et al.,
2011). As shown in Figure 4C, ivermectin-induced a fluorescence
FIGURE 4 | Examples of glycine- and ivermectin-mediated fluorescence
and current responses in mutant GlyRs. Current responses (black) and
fluorescence responses (red) were recorded simultaneously from Xenopus
oocytes expressing indicated α1 GlyRs. (A) Fluorescence responses
induced by glycine, but not ivermectin, in fluorescently labeled H201C
mutant GlyRs. (B) Fluorescence responses induced by glycine and
ivermectin in fluorescently labeled Q67C mutant GlyRs. (C) Fluorescence
responses induced by glycine and ivermectin in fluorescently labeled Q67C,
A288G, L233W triple-mutant GlyRs. These mutations convert ivermectin
into an antagonist of glycine-gated currents. The figure is modified from
Wang and Lynch (2012). Please refer to that paper for full experimental
details.
response at the N203C-L233W double mutant GlyR indicating
that ivermectin elicits a global conformational change even when
it inhibits glycine currents. These results indicate that ivermectin
induces conformational changes throughout the entire receptor,
despite its binding site being located immediately adjacent to
the M2 domain which houses the pore gate. By eliciting con-
formational changes in the neurotransmitter binding site, the
results provide a possible explanation as to how ivermectin poten-
tiates neurotransmitter-gated currents (Cully et al., 1994) and
permits glutamate to activate the otherwise glutamate-insensitive
C. elegans α GluClR (Etter et al., 1996; Hibbs and Gouaux,
2011).
CONCLUSIONS
Ivermectin binds to the TMD of Cys-loop receptors in a cleft
formed at the interface between adjacent subunits. A crystal struc-
ture of ivermectin binding to the C. elegans α GluClR revealed
the existence of hydrogen bonds linking ivermectin and the
transmembrane residues, L218, S260, and T285. However, site-
directed mutagenesis studies and amino acid sequence analysis
on other ivermectin-sensitive anionic Cys-loop receptors revealed
that hydrogen bonds with residues equivalent to S260 and T285
are not required for high ivermectin sensitivity at either the α1
GlyR or three other high ivermectin-affinity GluClRs. As the
hydrogen bond between the ivermectin C7-hydroxyl with the
L218 or equivalent residues is via the protein backbone carbonyl,
its existence cannot be readily tested via site-directed mutage-
nesis. However, this putative interaction requires confirmation
given that the ivermectin C7-hydroxyl is also close enough to
the carbonyl oxygen at the ivermectin C1 position to form an
intra-molecular hydrogen bond.
The slowly reversible (or irreversible) agonist activity of iver-
mectin is likely to be due to it accumulating in the membrane and
binding weakly (i.e., reversibly) to its site. An M3 domain glycine
residue at the mouth of the ivermectin binding cleft is essen-
tial for low nanomolar ivermectin potency, and indeed a glycine
at this position appears to be necessary and sufficient to confer
high ivermectin potency to anionic Cys-loop receptors. Despite
its functional importance, it is unlikely that bound ivermectin has
a significant energetic interaction with this residue when bound
to its site. It is more likely that side chains larger than glycine
form a physical barrier that inhibits ivermectin from efficiently
accessing its site in the cleft. Finally, ivermectin binding opens
the channel pore via a structural change that is different to that
induced by the endogenous neurotransmitter agonist. However,
ivermectin does simultaneously induce a global conformational
change that propagates to the neurotransmitter binding site, thus
suggesting one mechanism by which ivermectin may potentiate
neurotransmitter-gated currents. Together, this information pro-
vides important insights into the mechanisms of action of this
gold standard anthelmintic drug.
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